BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

Settlement Amounts:
BioNTech agreed to pay $791.5 million to the National Institutes of Health (NIH) and $467 million to the University of Pennsylvania (UPenn) to resolve disputes over royalty payments related to its COVID-19 vaccine13.

Pfizer Reimbursement:
Pfizer, BioNTech's partner in vaccine production, will reimburse BioNTech for $364.5 million of the royalties claimed by the NIH and $170 million for the royalties payable to UPenn23.

No Admission of Liability:
The agreements do not include an admission of liability by BioNTech3.

Future Royalties:
The settlements provide for BioNTech to pay a low single-digit percentage royalty on net sales of licensed products for 2024 onwards and establish a framework for licensing use in combination products3.

Resolution of Disputes:
The agreements resolve long-running disputes between BioNTech and the NIH and UPenn over royalty payments for the COVID-19 vaccine13.

Sources:

1. https://www.dw.com/en/covid-biontech-to-pay-12-billion-over-vaccine-royalties/a-71174072

2. https://www.nasdaq.com/articles/pfizer-reimburse-biontech-covid-vaccine-royalty-settlements

3. https://www.labpulse.com/business-insights/trends-and-finance/lawsuit/article/15711086/biontech-reaches-agreement-with-nih-penn-on-covid19-vaccine-royalties